Within this therapy, several responsive biomarkers could predict better ORR, including higher baseline TIL and tumor-infiltrating CD8+ T cells, and enhanced plasma TIM-3/CD152, as well as lower baseline plasma HGF/IL-8 and decreased plasma IL-8 level (Liu et al., 2021). The gene discussed is CXCL8; the disease is neoplasm.